Sexual Function Improvement With Prophylactic Sildenafil Citrate

MJ Zelefsky, D Shasha, RD Branco, M Kollmeier, RE Baser, X Pei, R Ennis, R Stock, N Bar-Chama, JP Mulhall

sildenafilMJ Zelefsky, D Shasha, RD Branco, M Kollmeier, RE Baser, X Pei, R Ennis, R Stock, N Bar-Chama, JP Mulhall
Prophylactic Sildenafil Citrate Improves Select Aspects of Sexual Function in Men Treated With Radiotherapy for Prostate Cancer
J Urol 2014 Sep 01;192(3)868-874 

ABSTRACT

PURPOSE
We studied adjuvant daily sildenafil citrate during and after radiotherapy for prostate cancer for erectile function preservation.

MATERIALS AND METHODS
We performed a randomized, prospective trial of 279 patients with localized prostate cancer treated with radiotherapy who received sildenafil citrate (50 mg daily) or placebo (2:1 randomization). Medication/placebo was initiated 3 days before treatment and continued daily for 6 months. Before therapy and 3, 6, 9, 12, 18 and 24 months after radiotherapy patients completed the IIEF questionnaire, including the erectile function domain, the I-PSS questionnaire and the RAND SF-36®. All IIEF domains were scored.

RESULTS
At 12 months erectile function scores were better for sildenafil citrate than placebo (p = 0.018), 73% of patients on sildenafil citrate vs 50% on placebo had mild/no erectile dysfunction (p = 0.024) and the sildenafil citrate arm had superior overall satisfaction (p = 0.027) and IIEF total scores (p = 0.043). At 24 months erectile function and IIEF scores were no longer significantly better for sildenafil citrate (p = 0.172 and 0.09, respectively) and yet overall satisfaction scores were higher (p = 0.033). Sexual desire scores in patients who received sildenafil citrate were higher at 24 months although they had completed drug therapy 18 months previously (p = 0.049). At 24 months 81.6% of patients on sildenafil citrate and 56.0% of those on placebo achieved functional erection with or without erectile dysfunction medication (p = 0.045).

CONCLUSIONS
Daily sildenafil citrate during and after radiotherapy for prostate cancer was associated with improved overall sexual function compared with placebo for various sexual function domains. To our knowledge this is the largest randomized, prospective, controlled trial to show the usefulness of a phosphodiesterase-5 inhibitor as a rehabilitation strategy in patients with prostate cancer who received radiation therapy.